• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

IDL Diagnostics

0.46 SEK

-4.41 %

Less than 1K followers

IDLDX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-4.41 %
+33.04 %
+30.37 %
+28.90 %
+16.67 %
-15.74 %
-21.01 %
-91.45 %
-80.90 %

IDL Diagnostics specializes in oncology and bacteriology. The company has a broad product portfolio, and develops, markets and sells blood and urine sample tests that are used by hospitals and clinics. The tests are intended to provide information for the detection of diseases such as urological cancers and typhoid fever. IDL Diagnostics targets patient groups in different parts of the world. The head office is in Stockholm.

Read more
Market cap
104.81M SEK
Turnover
71.43K SEK
Revenue
53.11M
EBIT %
-22.59 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Forum discussions
And today, the Chinese patent approval apparently came through
2/14/2025, 8:44 AM
by Arsene
9
Arocell’s Q4 report published. I quickly entered the figures into Excel, and it seems to be heading in a better direction. All in all, a pretty good quarter: best ever in terms of revenue, the first EBITDA-positive, and already the second positive quarter in terms of cash flow (last...
2/19/2025, 7:13 AM
by Kultapossu
7
IDL actually delivered a positive Q1. Redeye’s updated analysis: https://www.redeye.se/research/1167039/idl-diagnostics-q1-review-strong-start-to-2026
5/19/2026, 4:06 AM
by Arsene
4
The direction is clearly correct. This * Includes costs for goodwill amortization of KSEK 39,578 (39,578) for the period.* is puzzling, the result would be impressively positive, but that annual “amortization” still lurks in the figures, what on earth is it?
2/19/2025, 7:22 AM
by Arsene
4
Is something finally happening with Arocell, I wonder? In Redeye’s report IDL Diagnostics - Redeye, the “Momentum” section has now risen from 2 to 4 in a short period of time. The scale is 1-5, and it had been at 2 for quite a long time before this. On Placera’s forum Placera Forum...
2/14/2025, 6:39 AM
by Arsene
4
As of today, the name is IDL Diagnostics AB IDL Diagnostics IDL Diagnostics | Saving lives with diagnostics IDL Diagnostics ell is a Swedish diagnostics companywith the vision to improve the monitoring of oncological and bacterial diseases. I updated the title. The new ticker is ...
5/27/2025, 7:56 AM
by Torniojaws
3
Behind the link is also RE’s view of the quarter. They are hinting at a new urology-related acquisition. https://www.redeye.se/api/articles/download-file/c11b73c7-abef-3b6b-9d08-a8b87ffadd0f/AroCell%20Q2%3A%20First%20quarter%20with%20a%20positive%20cash%20flow
8/22/2024, 6:04 AM
by Kultapossu
3
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/8
2026

Interim report Q2'26

5/11
2026

Interim report Q3'26

18/2
2027

Annual report '26

Regulatory press release5/28/2026, 10:04 AM

Report from IDL Diagnostics Annual General Meeting

IDL Diagnostics
Regulatory press release5/28/2026, 10:04 AM

Kommuniké från IDL Diagnostics årsstämma 2026

IDL Diagnostics
Regulatory press release5/19/2026, 7:00 AM

Gustav Sten ny vd för IDL Diagnostics

IDL Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/19/2026, 7:00 AM

Gustav Sten appointed CEO of IDL Diagnostics

IDL Diagnostics
Press release5/18/2026, 10:16 AM

Redeye: IDL Diagnostics (Q1 Review): Strong start to 2026

IDL Diagnostics
Regulatory press release5/13/2026, 6:00 AM

IDL Diagnostics (publ) Interim Report January 1 – March 31, 2026

IDL Diagnostics
Regulatory press release5/13/2026, 6:00 AM

IDL Diagnostics (publ) Delårsrapport 1 januari – 31 mars 2026

IDL Diagnostics
Regulatory press release4/29/2026, 6:00 AM

Kallelse till årsstämma 2026 i IDL Diagnostics AB (publ)

IDL Diagnostics
Regulatory press release4/29/2026, 6:00 AM

Notice to the 2026 Annual General Meeting of IDL Diagnostics (publ)

IDL Diagnostics
Regulatory press release4/22/2026, 6:00 AM

IDL Diagnostics publicerar årsredovisningen för 2025

IDL Diagnostics
Regulatory press release4/22/2026, 6:00 AM

IDL Diagnostics publishes the Annual Report for 2025

IDL Diagnostics
Regulatory press release4/13/2026, 8:00 AM

Valberedningens förslag till styrelse i IDL Diagnostics till Årsstämman 2026

IDL Diagnostics
Regulatory press release4/13/2026, 8:00 AM

The nomination committee's proposal for the board of IDL Diagnostics for the Annual General Meeting 2026

IDL Diagnostics
Regulatory press release3/5/2026, 7:30 AM

Anders Hultman slutar som VD för IDL Diagnostics

IDL Diagnostics
Regulatory press release3/5/2026, 7:30 AM

Anders Hultman will be stepping down as CEO of IDL Diagnostics

IDL Diagnostics
Press release2/27/2026, 1:28 PM

Redeye: IDL Diagnostics (Q4 Review): Aims to broaden the sales model

IDL Diagnostics
Regulatory press release2/26/2026, 7:00 AM

IDL Diagnostics AB (publ) Delårsrapport 1 januari – 31 december 2025

IDL Diagnostics
Regulatory press release2/26/2026, 7:00 AM

IDL Diagnostics AB (publ) Interim Report January 1st to December 31st, 2025

IDL Diagnostics
Regulatory press release2/5/2026, 1:01 PM

IDL bildar ett joint venture-bolag med concile

IDL Diagnostics
Regulatory press release2/5/2026, 1:01 PM

IDL forms a joint venture with concile

IDL Diagnostics